Bone Therapeutics
Dr. Claudia D’Augusta has over 20 years of experience in the field of corporate finance, capital markets and M&A. She was most recently Chief Financial Officer of Therachon prior to its acquisition by Pfizer in early July 2019. Previously she served as General Manager at TiGenix after its acquisition by Takeda. Prior to this appointment, Claudia was Chief Financial Officer of TiGenix, where she led the company’s IPO on Nasdaq in 2016, served as a member of the Executive Committee and held responsibility for the Finance, Legal and Investor Relations areas. She also served as the Chief Financial Officer of Cellerix and led its merger with TiGenix, a company listed on Euronext. Before joining Cellerix in 2004, Claudia was Finance Director of Aquanima (Santander Group). Previous experiences include Deloitte & Touche in Milan and Apax Partners in Madrid.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Bone Therapeutics
Bone Therapeutics is a biopharmaceutical company developing cell therapy products for the treatment of osteo-articular diseases.